Maintenance Chemotherapy: An Evolving and Increasingly Acceptable Strategy in Cancer Management

Individual randomized phase 3 trials and meta-analyses of previously published studies have provided support for the general concept of the clinical utility of extending the duration of antineoplastic drug therapy in an effort to prolong (maintain) a favorable clinical state. This commentary briefly reviews data from several of these reports.